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Abstract
Background: Atopic Dermatitis is a chronic relapsing eczematous skin disease with increasing prevalence and
rising costs. It has a clear impact on a patient’s quality of life. Many patients are worried about the use of usual
care techniques, such as corticosteroids and antihistamine due to the widespread fear of adverse effects.
Complementary and alternative medical approaches have been employed to relieve symptoms of Atopic
Dermatitis. Hwangryunhaedoktang is among the most strongly preferred and widely used herbal medicines for
Atopic Dermatitis in Korea, as it causes very few serious adverse effects.
We aim to establish basic clinical efficacy and safety data for Hwangryunhaedoktang, which is approved as an
herbal medication by the Korean Food and Drug Administration, in adult patients with Atopic Dermatitis.
Methods/Designs: This study is a randomised, double blind, placebo-controlled, two-centre trial with two parallel
arms (Hwangryunhaedoktang and a placebo). The diagnosis of Atopic Dermatitis will be made according to the
criteria of Hanifin and Rajka by two different Oriental medicine doctors. We will include participants experiencing
typical conditions of intermittent or continuous Atopic Eczema for six or more months. Participants will receive
Hwangryunhaedoktang or a placebo-drug for eight weeks. The total duration of each arm is eleven weeks. Each
participant will be examined for signs and symptoms of Atopic Dermatitis before and after taking medication. A
follow-up to evaluate the maintenance of safety will be performed two weeks after the final administration of
medication.
Discussion: This trial will utilize high quality trial methodologies in accordance with consolidated standards of
reporting trials guidelines. It will provide evidence for the clinical efficacy and safety evaluation of
Hwangryunhaedoktang in adult patients with Atopic Dermatitis. Moreover, we will also employ health-related
quality of life questionnaires to assess the changes in quality of life.
Trial registration: Current Controlled Trials ISRCTN26218532
Background
Atopic Dermatitis (AD) is a chronic inflammatory pruri-
tic skin disease that is often associated with other atopic
disorders such as allergic rhinitis and asthma[1]. It is
characterised by poorly defined erythema with oedema,
vesiculation, and weeping in the acute stage and skin
thickening (lichenification) in the chronic stage[2].
These irritating symptoms result in a severely reduced
quality of life (QOL). In particular, itching that con-
tinues throughout the day and worsens at night causes
sleep loss and impacts everyday activities and psychoso-
cial well being [3,4].
The prevalence of AD has doubled or tripled in indus-
trialised countries during the past three decades; 15% to
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any medium, provided the original work is properly cited.30% of children and 2% to 10% of adults are affected[5].
Childhood disease continues into adulthood in a signifi-
cant number of individuals and represents a notable
burden[6]. AD should be regarded as a condition that
has the potential to be a major handicap involving con-
siderable personal, social and financial consequences
both for the family and for the community[7].
The most common therapies for the treatment of
moderate and severely relapsing AD are topical corticos-
teroids, emollients, oral antihistamines, antibiotic agents,
immunosuppressive agents, or non-pharmacologic
approaches[2]. However, these methods do not ensure
successful treatment in every patient with AD. Oral cor-
ticosteroids improve the lesions of AD, but a disease
flare may occur when these medications are stopped. In
addition, the local and systemic side effects of topical
steroids, such as skin atrophy, hypo-pigmentation, adre-
nal suppression, cataracts, glaucoma, and growth retar-
dation, are well recognised[8]. Although pruritus can be
treated with antihistamines or tricyclic anti-depressants,
these agents can affect a child’s ability to learn or an
adult’s ability to drive and work[9].
In this context, various complementary and alternative
medicine (CAM) treatments have been administered for
AD in clinical practice. Complementary and alternative
therapies are commonly used because of concerns about
the potentially adverse effects of conventional therapies
and frustration with the lack of appropriate regular use
[10]. Some studies have reported the effectiveness of
acupuncture or herbal medicine, which is the most pop-
ular form of CAM therapy, for the treatment of AD
when used alone or concomitantly with usual care
[10-12]. In the few number of trials that have been con-
ducted, the quality and the small sample sizes of these
studies make it difficult to reach firm conclusions con-
cerning these treatments. Well-designed, randomised,
controlled trials are needed to examine the efficacy of
complementary and alternative treatments for AD.
The purpose of this study is to establish the basic
clinical efficacy and safety data for Hwangryunhaedok-
tang, which is approved as an herbal medication by the
Korean Food and Drug Administration (KFDA). The
use of Hwangryunhaedoktang for AD is based on the
principles of Traditional Korean Medicine (TKM). In
this medical tradition, Hwangryunhaedoktang is admi-
nistered to treat the pattern of wind-heat, blood-heat,
or blood deficiency associated with AD[13]. Also, sev-
eral studies demonstrated that Hwangryunhaedoktang
exerts anti-inflammatory, antibiotic, antioxidative, and
immunosuppressive activities[14,15]. However, there
are no relevant randomised, controlled clinical trials
regarding AD.
We will conduct a randomised, double-blind, placebo-
controlled, two-centre trial of Hwangryunhaedoktang in
adult patients with AD. Because of the absence of a gold
standard for the treatment of AD, this trial will be con-
ducted to determine the effectiveness of these herbal
medicines by comparison with a placebo controlled
group.
Methods/Design
A randomised, double-blind, placebo-controlled, two-
centre trial will be conducted at the Wonkwang Univer-
sity Oriental Medical Centre in Gunpo and at the Sangji
University Oriental Medical Centre in Wonju, Korea.
Participants fulfilling eligibility criteria will be selected.
Enrolled participants will be randomly allocated to two
parallel groups: the Hwangryunhaedoktang and placebo
arms. Each participant will be examined for signs and
symptoms of AD before and after taking medication. A
follow-up to evaluate the maintenance of safety will be
performed by phone-call (Figure 1).
Recruitment
We will recruit participants by advertisement in local
newspapers and on the websites of local medical centres
in Gyeonggi-province and Gangwon-province. Respon-
dents will be contacted by clinical trial coordinators
(CRC) to determine eligibility via a telephone pre-
screen. If an applicant meets the study criteria, he or
she will be invited to the clinical research centres and
be examined for eligibility. Oriental medicine doctors
and Internal medicine doctors will conduct the screen-
ing together to improve the quality of eligibility assess-
ment. Oriental medicine doctors will manage the whole
process of screening. Internal medicine doctors will
assess the complete blood cell count (CBC), erythrocyte
sedimentation rate (ESR), blood chemistry, PA chest
film, and urine analysis to exclude patients with serious
liver and kidney disease.
Inclusion criteria
Eligible participants of both sexes who are 19 years or
older will be enrolled according to the inclusion and
exclusion criteria. The diagnosis of AD will be made
according to the criteria of Hanifin and Rajka by two
different Oriental medicine doctors. We will include
participants experiencing the typical conditions of inter-
mittent or continuous Atopic Eczema for six or more
months. Participants will be instructed to discontinue
other treatments for AD during the run-in, treatment,
and follow-up periods. Written informed consent will be
obtained from each participant.
Exclusion criteria
Participants will be excluded if they suffer from serious
medical conditions, such as uncontrolled hypertension,
diabetes mellitus requiring insulin injection, past or
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Patient recruitment 
Screening of Patients by Eligibility Criteria 
Run-in Phase for 1 week 
Randomization 
Group A (n=50) 
Hwangryunhaedoktan
g 
Group B (n=50) 
Placebo 
Medications for 2 weeks (1st)   
Outcome Assessment 2 weeks after the first medication 
administration  
Medications for 2 weeks (2nd)   
Outcome Assessment 4 weeks after the first medication 
administration 
Follow-up (2 weeks after treatment discontinuation)
Medications for 4 weeks (3rd)   
Outcome Assessment 8 weeks after the first medication 
administration 
Figure 1 Study Flow Chart.
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Page 3 of 8current malignancy, liver or kidney dysfunction, anae-
mia, active pulmonary tuberculosis, or other severe
dermatitis or infectious or systemic diseases incompati-
ble with treatment with herbal medicines. The exclu-
sion criteria are as follows: administration of steroids
and immunosuppressants per os within one week of
interview; the use of other forms of AD treatment
except those involving external application; pregnancy,
lactation, or the lack of a form of contraception;
underlying disease or history of severe hepatic disease,
abnormal results for liver function test (greater than
twice the upper limit of normal); participation in
another clinical trial within one month of enrolment;
hypersensitivity or allergic reactions to herbal medi-
cines that are related to this trial; diseases that can
affect the absorption of drugs or disordered digestion
after surgery related to such a disease; inability to
understand written consent or engage in this study
due to mental retardation or other emotional or men-
tal problems; or judgment by experts that the potential
subject’s participation is inappropriate.
Exclusion will be primarily based on the information
provided by the patients. Also, additional examinations,
such as CBC, ESR, blood chemistry, PA chest film, urine
analysis, and vital signs will be performed before the
trial to ensure that the patients do not suffer from these
diseases. Over-the-counter (OTC) drugs will be allowed
for the management of headaches, dyspepsia, etc.; how-
ever, participants will be gently advised to reduce the
doses, stop taking supplements, or refrain from adding
other supplements to their regimen. Some OTC drugs,
such as those containing anti-histamine or anti-aller-
genic agents, will not be allowed, as there are concerns
that these drugs might have direct impacts on AD.
These restrictions will be based on the information
provided by patients, and researchers will then evaluate
whether or not some of these components would impact
AD. We will record the drugs taken by each participant
at every visit, and participants will be asked to notify us
of any changes in their medication/supplement regimen.
Additional herbal prescriptions, acupuncture treatments,
or therapeutic interventions by other clinicians will not
be allowed during the trial period. The complete eligibil-
ity criteria are in Appendix 1.
Sample size
We wished to estimate the sample size that would be
sufficient to detect significant differences in the SCOR-
ing Atopic Dermatitis (SCORAD) index between the
experimental and control groups. Sample size was deter-
mined prospectively, as described in a previous study
[16,17]. The mean and standard deviation of expected
difference scores in SCORAD were 13 and 20 between
the experimental and control group. The following
formula was used to estimate the sample size for a two-
group trial:
2(Zα/2 + Zβ)
2σ2
(μc − μt)
2
Calculations were performed using 80% power, a 5%
significance level, and a 25% dropout rate. The required
sample size was approximately 37 participants for each
group. We plan to enrol 100 participants in each of the
two groups, allowing for a 25% withdrawal rate.
Randomisation and allocation
The randomisation procedure will be guaranteed by the
authorised Clinical Research Organisation (CRO). An
expert on statistics from CRO who have no contact with
the study participants will conduct the randomisation of
participants. Participants will be assigned random num-
bers via random number generator program (Microsoft
Office Excel 2007). Random numbers will be sent to
each centre, and randomisation table will be kept blind-
ing by CRO during the research period. Ultimately, 100
participants will be randomised into the two groups at
the two centres. However, the number of subjects
planned for each location is not fixed. Opaque sealed
envelopes containing serial numbers will be delivered to
each centre. Opaque sealed randomisation table kept by
CRO should be opened as a Standard Operating Proce-
dure (SOP). If it has to be opened in urgent situation
dealing with serious adverse events, primary investigator
must report that to the CRO. Before the random assign-
ment, all participants will be informed that they would
be allocated to one of two groups. Random allocation
will be conducted at the second visit. Random numbers
with their corresponding participants will be determined
by the order of the time of second visit. The allocation
results will not be announced to the participants until
the last visit of the last randomised participant.
Blinding
In this trial, investigators will not be in contact with the
CRC, the clinical pharmacist, or the statistician. The
success of blinding will be assessed at each participant’s
last visit. Researchers who are blinded to the allocation
results will perform the outcome assessment. The blind-
ing procedure will also be verified by the authorised
CRO.
Treatment protocol
Participants will receive Hwangryunhaedoktang or a pla-
cebo-drug for eight weeks. Oral administration occurs
according to the following statement:
Patients in group 1 will receive Hwangryunhaedoktang
and instructions on how to make the tea; they should
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water three times a day 30 minutes after meals.
Patients in group 2 will receive the placebo medicine
(powdered extract), used in the same way as in group 1.
The defined daily doses (DDDs) of these herbal medi-
cines should be determined based on the specifications
and analytical procedures of drug products in KFDA
guidelines. However, no pilot study has been reported
so far.
Experimental medicines (Hwangryunhaedoktang)
Hanpoong Pharm and Foods Co., Ltd., produced the
Hwangryunhaedoktang and the placebo medicine
according to Korea Good Manufacturing Practice
(KGMP) standards.
Hwangryunhaedoktang used in this trial is a brown,
bitter herbal extract. Hwangryunhaedoktang is com-
posed of four herbs: Powdered extract of Scutellaria bai-
calensis (334.00 mg as Baicalin), 1.67 g; Powdered
extract of Gardenia jasminoides, 1.67 g; Powdered
extract of Coptis chinensis (116.20 mg as Berberine),
0.83 g; Powdered extract of Phellodendron Amurense
(19.92 mg as Berberine), 0.83 g.
Placebo medicine
Hanpoong Pharm and Foods Co., Ltd., developed a
homogenous powdered extract of brown colour, which
was made by mixing 3.489 g of lactose, 1.495 g of
starch, and 0.016 g of pigments approved by KFDA. The
colour, form, weight, odour, and taste of the placebo are
very similar to the treatment medicines.
Primary outcome measurement
SCORAD index will be used as the primary outcome
variable. SCORAD is a clinical tool for assessing the
severity of AD as objectively as possible. SCORAD con-
sists of three scales: extent, intensity, and subjective.
The severity of eruptions on lesions is evaluated on a 4-
point scale (0: none, 1: mild, 2: moderate, 3: severe) by
scoring the erythema, oedema, oozing, excoriation,
lichenification, and xerosis. SCORAD is calculated by
t h ee q u a t i o nA / 5+7×B / 2+C .I nt h i se q u a t i o n ,Ai s
t h ep e r c e n t a g eo fb o d ya r e aw i t has k i nr a s h ,Bi st h e
total score of erythema, oedema, oozing, excoriation,
lichenification, and xerosis, each of which was evaluated
on a 4-point scale, and C is the visual analogue scale
(VAS, a scale from 0 to 10) for subjective assessment of
both itching and sleep loss[18-20]. It will be measured
at treatment initiation, at two weeks after the first medi-
cation administration, at four weeks after the first medi-
cation administration, and at eight weeks after the first
medication administration.
Secondary outcome measurement
Secondary outcome measurements include the total IgE
and eosinophil counts. These will be measured at treat-
ment initiation, at four weeks after the first medication
administration, and at eight weeks after the first medica-
tion administration. The EuroQoL 5-Dimension (EQ-
5D), the Health Utilities Index Mark 3 (HUI3), and the
Dermatology Life Quality Index (DLQI) will be mea-
sured at treatment initiation and at eight weeks after the
first medication administration, as a measure of health
outcomes. The data collection schedule is detailed in
Table 1.
Patient safety
All patients will undergo routine testing that included
the following: complete blood cell count (CBC), erythro-
cyte sedimentation rate (ESR), and blood chemistry, as
well as PA chest film and urine analysis before randomi-
sation and immediately after completing the treatment.
Vital signs will be measured at every visit. These tests
help to identify and exclude patients with serious liver
Table 1 Data Collection Schedule
Period Screening Treatment period Followup
Visit 1st
(D -7)
2nd
(D 1)
3rd
(D 15)
4th
(D 29)
5th
(D 57)
(D 71)
Informed consent ◯
Demographic characteristics ◯
Medical History ◯
Safety Assessment ◯ ◯ ◯◯◯
Total IgE, Eosinophil count ◯◯ ◯
SCORAD Index ◯ ◯◯◯
Dermatology Life Quality Index ◯◯
EQ-5D ◯◯
Health Utilities Index Mark 3 ◯◯
Adverse effects ◯◯◯ ◯
Blinding Assessment ◯
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ness. Investigators will assess a significant result in these
tests according to explicit criteria defining the incidence
and intensity of adverse events. Also a causality evalua-
tion of adverse drug reactions will be discussed.
Statistical analysis
Analyses will be performed for two populations: 1) an
intention-to-treat population consisting of all rando-
mised participants who have at least one measurable
outcome report following treatment (missing data are
replaced with the last observation values) and 2) a per-
protocol population including only participants without
major protocol deviations. All data will be descriptively
analysed. All main analyses will be based on the inten-
tion-to-treat population and conducted using LOCF
(last observation carried forward) imputation method.
For primary outcome measures, the mean differences
from baseline values to the end of treatment will be
compared using a independent T-test (Expected non-
centrality parameter = 2.87, Critical t = 1.99, Power =
0.80). Paired T-test or non-centrality Wilcoxon rank
sum test will be used for comparing safety variables.
Repeated measure ANOVA (analysis of covariance) or
repeated measure ANCOVA tests will also be performed
for within-group and between-group analyses. Baseline
data will be collected on each participant at randomisa-
tion in trial can be used to describe the population of
patients, to assess comparability of treatment groups, to
achieve balanced randomisation, to adjust possible com-
foundings for prognostic factors, and to undertake sub-
group analyses. We will exercise caution when drawing
conclusions from subgroup findings.
Statistical analyses will be performed using the
STATA statistical package program (ver. 11.0), and the
level of significance is established at a = 0.05.
Data and safety monitoring
To maintain the quality of this trial, monitoring will be
conducted by Pharma CRO, a CRO located in Gyeonggi,
Korea. Investigators can also be convened to discuss
practical issues that might be encountered, such as deal-
ing with serious adverse events, revising the protocol,
and addressing certain important issues that might be
raised by investigators and participants.
We defined adverse events as unintended signs, symp-
toms, or diseases occurring after treatment that were
not necessarily related to the intervention. The safety
assessment is based primarily on the frequency of
adverse events, which include all serious adverse events.
Information regarding adverse events will be sum-
marised by presenting the number and percentage of
participants experiencing any adverse events. During the
trial, all adverse events will be observed in detail and
documented in case report forms (CRFs).
Ethics
Written consent will be obtained from each participant.
This study protocol was approved by the institutional
review boards (IRB) of the Wonkwang University Orien-
tal Medical Centre, Sangji University Oriental Medical
Centre, and Wonkwang University Medical Centre.
Discussion
Herbal products have gained increasing popularity, and
are now used by approximately 20% of the population
in the United States[21]. But, use of botanicals is still
relatively small compared to use of mainstream medi-
cine in this continent. In contrast, the situation in Korea
could not be more different[22]. Almost 60% of the
total population had the experience of being treated by
TKM[23]. Hwangryunhaedoktang is widely used herbal
medicines for AD in Korea. There is a high possibility
that some participants would already have an experience
of being treated by Hwangryunhaedoktang. This trial
will be conducted to assess the effectiveness of Hwan-
gryunhaedoktang by comparison with a placebo con-
trolled group. If participants would discriminate
between placebo and experimental medicines during the
treatment period, results of this trial may be affected by
selection and detection bias. In order to prevent this
situation, we developed a homogenous powdered
extract. The colour, form, weight, odour, and taste of
the placebo are very similar to the treatment medicines,
Hwangryunhaedoktang. We will assess the success of
blinding at each participant’s last visit.
Most CAM trials do not describe the generation of the
random sequence, an adequate method of allocation
concealment, and the number and reasons for drop outs
and withdrawals[24,25]. In this context, there are two
unique features in this trial. Firstly, we developed the
protocol in conjunction with the recommendations of
consolidated standards of reporting trials (CONSORT)
checklists for herbal interventions. Secondly, we adapted
outcome measurements from prior studies on the herbal
medicines for AD after reviewing the related research
literatures.
This protocol is approved as an Investigational New
Drug Application (IND) by the KFDA. This trial will
provide for the clinical efficacy and safety evaluation of
Hwangryunhaedoktang, herbal extracts, in adult patients
with AD. We will also estimate the QOL changes from
health-related quality of life questionnaires. Results of
this trial will provide important information, in addition
to addressing the feasibility of conducting a larger study
using this methodology and statistical approaches as
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it could provide a foundation for the understanding of
health economic analysis.
Abbreviation
AD: Atopic Dermatitis; ANOVA: analysis of variance;
ANCOVA: analysis of covariance; CAM: complementary
and alternative medicine; CBC: complete blood cell
count; CONSORT: Consolidated Standards of Reporting
Trials; CRC: clinical trial coordinators; CRFs: case report
forms; CRO: Clinical Research Organisation; DDDs:
defined daily doses; DLQI: Dermatology Life Quality
Index; ESR: erythrocyte sedimentation rate; EQ-5D:
EuroQoL 5-Dimension; KFDA: Korean Food and Drug
Administration; HUI3: Health Utilities Index Mark 3;
IND: Investigational New Drug Application; IRB: institu-
tional review board; KGMP: Korean Good Manufactur-
ing Practice; KHIDI: Korean Health Industry
Development Institute; LOCF: Last Observation Carried
Forward; OTC: Over the counter; QOL: Quality of Life;
SCORAD: SCORing Atopic Dermatitis; SOP: Standard
Operating Procedure; TKM: Traditional Korean Medi-
cine; VAS: Visual Analogue Scale.
Appendix 1. Eligibility Criteria
Inclusion criteria
1. Age greater than 19 years, either sex
2. Typical conditions of intermittent or continuous
atopic eczema
2.1. Duration of more than 6 months
2.2. Satisfied Hanifin and Rajka’s criteria for atopic
dermatitis
3. Diagnosed with adult atopic dermatitis by two dif-
ferent oriental medicine doctors
4. Written and informed consent
Exclusion criteria
1. Other dermatitis or systemic disease except for
atopic eczema
2. Administration of steroids and immunosuppres-
sant per os (by mouth) within one week of the inter-
view (topical application not relevant)
3. Women who are pregnant, lactating, or without
contraception
4. Clinical severe hepatic disease or abnormal liver
function tests at least twice the upper limit of
normal
5. Participation in another clinical trial within the
last month
6. Hypersensitivity or allergy to drugs
7. Disease which can affect the absorption of drugs,
or disordered digestion after surgery related to the
disease
8. Cannot understand written consent or follow this
study
8.1. Mental retardation
8.2. Mental or emotional problems
9. Judged by expert as inappropriate to participate in
this study
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